| Literature DB >> 23574753 |
Jessica Stahl, Stefanie Mielke, Wolf-Rüdiger Pankow, Manfred Kietzmann.
Abstract
BACKGROUND: An in-vitro setup was established in order to determine a) the diffusion activities of eight otic preparations (Aurizon®, Eas Otic®, Epi Otic®, Otifree®, Otomax®, Panolog®, Posatex®, Surolan®) through synthetic cerumen, and b) the ceruminolytic capacity and impregnation effects of these products. The main lipid classes of canine cerumen produced with moderate, non-purulent otitis externa were determined by thin layer chromatography and were subsequently used to produce a standardised synthetic cerumen (SCC). SCC was filled into capillary tubes, all of which were loaded with six commercially available multipurpose otic medications and two ear cleaners, each mixed with two markers in two experimental setups. These two marker compounds (Oil red O and marbofloxacin) were chosen, since they exhibit different physicochemical drug characteristics by which it is possible to determine and verify the diffusion activity of different types of liquids (i.e. the otic preparations). A synthetic cerumen described in the literature (JSL) was also used for comparison as its lipid composition was different to SCC. The diffusion activities of the otic preparations through both types of synthetic cerumen were studied over 24 hours. A second in-vitro experiment determined both the ceruminolytic activity and impregnation effect of the otic preparations by comparing the weight loss or weight gain after repeated incubation of JSL.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23574753 PMCID: PMC3641987 DOI: 10.1186/1746-6148-9-70
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Lipid composition of canine cerumen of 12 healthy dogs and 12 dogs with acute moderate, non-purulent OE
| | | | ||
|---|---|---|---|---|
| Alkanes | n.q. | n.q. | n.q. | n.q. |
| Cholesterol | 1.68 | 0.66 | 1.55 | 1.28 |
| Cholesteryl sulphate | 0.12 | 0.13 | 0.08 | 0.13 |
| Ceramide [AP] | 0.78 | 0.38 | 0.71 | 0.75 |
| Ceramide [AP/AS] | 0.48 | 0.23 | 0.35 | 0.35 |
| Ceramide [AS] | 0.31 | 0.22 | 0.25 | 0.27 |
| Ceramide [EOS] | n.d. | n.d. | n.d. | n.d. |
| Ceramide [NP] | 0.45 | 0.22 | 0.48 | 0.34 |
| Ceramide [NS] | 0.33 | 0.27 | 0.66 | 0.56 |
| Fatty acid ester | 8.50 | 3.36 | 5.79 | 4.47 |
| Free fatty acids | 1.50 | 0.62 | 1.42 | 1.21 |
| Galactocerebrosides | 0.31 | 0.34 | 0.23 | 0.50 |
| Phospholipids | 0.08 | 0.12 | 0.29 | 0.60 |
| Squalene | 2.08 | 2.41 | 3.19 | 2.58 |
| Sterol ester* | 14.30 | 10.24 | 6.97 | 5.07 |
| Triglycerides | 21.01 | 6.08 | 18.89 | 13.99 |
The quantities are expressed as means and standard deviations after determination with thin layer chromatography, n.d. = not detectable, n.q. = not quantifiable; asterisks indicate p < 0.05 (t-test with Mann Whitney test, two-tailed).
Figure 1Diffusion of Oilred O supplemented to eight otic preparations through synthetic canine cerumen (SCC), means ± standard deviations, n = 6, asterisks (***) indicate p < 0.001 after 1440 h (Aurizon® vs. seven other formulations and control).
Figure 2Mean diffusion of Oilred O supplemented to eight otic preparations through synthetic canine cerumen (JSL), n = 6, asterisks (***) indicate p < 0.001 after 1440 h (Aurizon® vs. seven other preparations and control).
Figure 3Oil red O diffusion through synthetic canine cerumen (SCC) after 24 hours, 1 = control (SCC), 2 = Aurizon®, 3 = Epi Otic®, 4 = Eas Otic®, 5 = Panolog®, 6 = Posatex®, 7 = Otomax®, 8 = Surolan®, 9 = Otifree®. The yellow box indicates the approximate area of SCC sampling for the HPLC analysis of supplemented marbofloxacin.
Percentage of standardised synthetic cerumen (JSL) removed after each run (Test)
| | |||||
|---|---|---|---|---|---|
| Aurizon® | −42.7 ± 14.4 | −29.8 ± 4.2 | −29.3 ± 4.9 | −34 | −5.3 ± 3.8 |
| Eas Otic® | −46.2 ± 2.9 | −3.0 ± 8.7 | −17.7 ± 14.7 | −22.3 | 2.7 ± 6.5 |
| Epi Otic® | −9.2 ± 3.1 | −12.4 ± 3.2 | −11.8 ± 2.5 | −11.2 | −7.1 ± 2.0 |
| Otifree® | −8.1 ± 4.3 | −3.5 ± 2.7 | −10.3 ± 5.6 | −7.3 | 5.6 ± 1.2 |
| Otomax® | −68.6 ± 6.7 | −19.3 ± 10.0 | −22.7 ± 6.3 | −36.9 | −18.5 ± 3.0 |
| Panolog® | −57.8 ± 10.4 | −15.5 ± 5.8 | −34.7 ± 8.4 | −36 | −5.4 ± 7.1 |
| Posatex® | −58.2 ± 10.8 | −32.4 ± 11.8 | −47.4 ± 9.9 | −46 | −64.4 ± 5.5 |
| Surolan® | −20.4 ± 8.6 | −19.4 ± 7.5 | −23.5 ± 8.8 | −21.1 | −3.7 ± 7.1 |
| Control (water) | −2.5 ± 1.1 | −3.4 ± 1.6 | −2.6 ± 1.0 | −2.8 | −2.1 ± 3.3 |
* Weighing was performed after washing with cold water (mean ± standard deviation), n = 4 loadings per test.
Positive values indicate ceruminolysis; negative values indicate that there has been impregnation of the product.
Figure 4Mean percentage of standardised synthetic cerumen (JSL) removed after Tests 1–3, n = 4 loadings; positive values indicate ceruminolysis, negative values indicate that there has been impregnation of the product.
Figure 5Mean percentage of standardised synthetic cerumen (JSL) removed after Test 4; weighing was performed after washing with cold water in order to remove all product residues, n = 4 loadings per Test. Positive values indicate ceruminolysis; negative values indicate that there has been impregnation of the product.
Figure 6Thin layer chromatography presenting the composition of canine cerumen in comparison to lipid standards.
Otic preparations with their active ingredients, excipients and galenic formulation; the asterisks indicate the ear cleaners
| Aurizon® | Marbofloxacin, clotrimazole, dexamethasone acetate | Propyl gallate (E310), sorbitan oleate, silicon dioxide, medium-chain triglycerides | suspension | Vétoquinol GmbH, Ravensburg, Germany, Batch number 1A18750/03605877138794 |
| Eas Otic® | Hydrocortisone aceponate, miconazol nitrate, gentamicin sulphate | Liquid paraffin | suspension | Virbac Tierarzneimittel GmbH, Bad Oldesloe, Germany, Batch number 3HLS |
| Otomax® | Gentamicin sulphate, betamethasone valerate, clotrimazole | Liquid paraffin, hydrocarbon gel | suspension | Intervet Deutschland GmbH, Unterschleissheim, Germany, Batch number APNA 1231 |
| Panolog® | Triamcinolone acetonide, neomycin sulphate, nystatine, thiostreptone | Plastibase 10W (95% liquid paraffin, 5% polyethylene) | suspension | Novartis Tiergesundheit GmbH, Munich, Germany, Batch number 0404811922901734721 |
| Posatex® | Orbifloxacin, momethasone furoate, posaconazole | Liquid paraffin, hydrocarbon gel (5% polyethylene in 95% mineral oil), lauric acid | suspension | Intervet Deutschland GmbH, Unterschleissheim, Germany, Batch number 1117101 |
| Surolan® | Prednisolone acetate, polymyxin B sulphate, miconazol nitrate | Silicon dioxide, liquid paraffin | suspension | Janssen Animal Health, Neuss, Germany, Batch number BHB1L02 |
| Epi Otic® | | Salicylic acid, dictyle sodium, sulfosuccinate, chloroxylenol, EDTA, monosaccharides | solution | Virbac Tierarzneimittel GmbH, Bad Oldesloe, Germany, Batch number 3EP8 |
| Otifree® | Propylene glycol, cremophor, calendula extract, basil oil, water | solution | Vétoquinol GmbH, Ravensburg, Germany, Batch number 0B4953K | |
Physicochemical properties of Oil red O and marbofloxacin
| Molecular weight (g/mol) | 409 | 362 |
| LogP | 7.577 | −0.835 |
| Melting point (°C) | 120 | 268 |